Drug Topics
OCTOBER 14, 2024
Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.
STAT
OCTOBER 17, 2024
Jazmin Evans was waiting on dialysis for four years before finally, on the Fourth of July last year, she received a kidney transplant. “Now I say the fireworks are for me,” said Evans, who was diagnosed with kidney disease when she was 17. She would have been waiting even longer had it not been for a shift, in 2021, in the way that physicians calculate kidney function for Black patients like her.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
OCTOBER 12, 2024
High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.
STAT
OCTOBER 16, 2024
If you’re aware of the H5N1 bird flu outbreak in U.S. dairy cattle — you may have seen some headlines or read something on social media — perhaps you are wondering what the fuss is about. Yes, there have been nearly a couple dozen human cases, but all have had mild symptoms. The virus does not decimate herds in the way it does poultry flocks; most — though not all — of the infected cows come through the illness OK.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
OCTOBER 15, 2024
Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a ro | Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a rocky fiscal 2024.
pharmaphorum
OCTOBER 14, 2024
Eli Lilly may invest $364m in the UK and work with the government to tackle serious public health challenges including obesity.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 14, 2024
The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.
STAT
OCTOBER 16, 2024
The emails from UnitedHealth Group managers were filled with exclamation marks and pleasantries about the weather. But the underlying message to doctors in late 2020 was persistent and urgent: Hit your targets to see more patients. We need to bring in more money. At the time, deaths from Covid-19 were surging, and no vaccine was available.
Fierce Healthcare
OCTOBER 11, 2024
This story was reported in partnership with Uncloseted Media, a nonpartisan, investigative, LGBTQ | Ending the HIV epidemic hinges on both treatment and prevention, particularly through access to PrEP. For at-risk individuals living in the U.S. South—where HIV is a daunting reality—PrEP use is very low compared to the number of new HIV cases.
The Guardian - Pharmaceutical Industry
OCTOBER 16, 2024
Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens. People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
OCTOBER 10, 2024
Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.
Pharmacy Times
OCTOBER 11, 2024
This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.
STAT
OCTOBER 15, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Hello, you spry bunch. We’re coming to you on a Tuesday after yesterday’s holiday. What are you looking to read more about as the year winds down? Let us know: bob.herman@statnews.com.
Fierce Healthcare
OCTOBER 15, 2024
The Drug Enforcement Administration is poised to extend pandemic-era telehealth prescribi | The third temporary extension is rumored to be for just one year, punting the deadline for the next administration to negotiate permanent rules to December 2025. Telemedicine companies, including those that prescribe Adderall, will be able to continue prescribing as they have since 2020.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
OCTOBER 14, 2024
Four days after a compounding industry group filed a lawsuit against the FDA | Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products from its shortage list, the U.S. regulator is taking a second look at its decision.
Drug Topics
OCTOBER 15, 2024
The financial burden of in vitro fertilization (IVF) medications has become increasingly prohibitive, limiting the availability of fertility treatments for many.
Pharmacy Times
OCTOBER 14, 2024
Artificial Intelligence (AI) is transforming drug development by automating routine tasks, enhancing clinical trials, and expediting drug discovery, ultimately leading to more personalized treatments.
STAT
OCTOBER 15, 2024
It was a dramatic call to action by the American Heart Association: The organization declared its decade-long goal culminating in 2020 was to slash deaths from cardiovascular disease and stroke by 20%. It also promised in its scientific journal to move all Americans toward “ideal cardiovascular health.” That never happened. Deaths did decrease by 15% from 2010, but it was a “disappointment” that fatalities linked to conditions like high blood pressure, heart failure,
Fierce Healthcare
OCTOBER 11, 2024
Wolters Kluwer Health, a big player in clinical decision support solutions, is teaming up with Abridge to integrate UpToDate into its AI-based medical note-taking tool. | Wolters Kluwer Health, a big player in clinical decision support solutions, is teaming up with Abridge to integrate UpToDate into its AI-based medical note-taking tool.
Fierce Pharma
OCTOBER 15, 2024
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA. In the complaints, GSK says it hopes to recover a “reasonable royalty” tied to Moderna’s vaccine sales, plus damages.
Drug Topics
OCTOBER 16, 2024
Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.
Pharmacy Times
OCTOBER 14, 2024
In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.
STAT
OCTOBER 14, 2024
It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age. An observational study published Monday in JAMA Network Open found that children and adolescents were one-and-a-half times more likely to be diagnosed with the metabolic disorder in the months after having Covid-19 compared to similar kids who weathered other respiratory infections.
Fierce Healthcare
OCTOBER 10, 2024
Intravenous fluid shortages appear to be affecting the majority of the nation’s healthcare providers, who as a result are already beginning to cancel procedures, survey data published Thursday show | Premier said 86% of its provider members are reporting shortages, and more than half have less than 10 days supply on hand. Respondents also said they were beginning or considering procedure cancellations, and have begun receiving solicitations from "unapproved, gray market suppliers.
Fierce Pharma
OCTOBER 14, 2024
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly has notched a trial win over a major rival in a head-to-head study.  | Eli Lilly's drug outperformed Johnson & Johnson's established Stelara in a phase 3 study that looked at histologic disease responses over 52 weeks.
Drug Topics
OCTOBER 17, 2024
In posters presented at the American College of Clinical Pharmacy 2024 Annual Meeting, researchers explored the implementation of collaborative care programs within various health systems.
Pharmacy Times
OCTOBER 15, 2024
Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.
STAT
OCTOBER 14, 2024
When the U.S. health care system pivoted to meet Covid-19 in 2020, routine health visits and screenings where many cancer cases would have been caught didn’t happen. It wasn’t ideal, but many health experts thought that as the country opened back up, screenings would help “catch up” to these missed cases. A new paper published Monday in JAMA Network Open suggests that didn’t happen as quickly as experts had hoped.
Fierce Healthcare
OCTOBER 10, 2024
Just 40% of Medicare Advantage prescription drug plans offered in 2025 achieved a score of four stars or higher, the Centers for Medicare & Medicaid Services (CMS) revealed Oct. 10. | It's harder than ever for Medicare Advantage plans to score well on star ratings. Here's how they performed for 2025.
Fierce Pharma
OCTOBER 11, 2024
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.
Drug Topics
OCTOBER 17, 2024
The National Community Pharmacists Association surveyed over 4000 independent pharmacy owners and managers for their thoughts on the 10 drugs selected for Medicare price negotiations.
Pharmacy Times
OCTOBER 14, 2024
Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPPA-compliant photos to celebrate American Pharmacist Month.
STAT
OCTOBER 14, 2024
Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has seen an even more significant amount of activity: autoimmune diseases. Companies that are developing new medicines for autoimmune conditions, as well as other immune system disorders, have brought in more money and closed more deals so far this year than most other areas, including the cardiometabolic field, data from investment bank Oppenh
pharmaphorum
OCTOBER 15, 2024
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.The Danish drugmaker has offered $60 per share for California biotech Longboard, with the main asset in the deal bexicaserin, an oral, centrally acting serotonin 5-HT 2C receptor super-agonist in late-stage testing for seizures associated with rare forms of epilepsy.
Expert insights. Personalized for you.
230 
Let's personalize your content